Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that leads to dementia and behavioral changes. Extracellular deposition of amyloid plaques (Aβ) and intracellular deposition of neurofibrillary tangles in neurons are the major pathogenicities of AD. However, drugs targeting these therapeutic targets are not effective. Therefore, novel targets for the treatment of AD urgently need to be identified. Expression of the mesoderm-specific transcript (Mest) is regulated by genomic imprinting, where only the paternal allele is active for transcription. We identified hypermethylation on the Mest promoter, which led to a reduction in Mest mRNA levels and activation of Wnt signaling in brain tissues of AD patients. Mest knockout (KO) using the CRIPSR/Cas9 system in mouse embryonic stem cells and P19 embryonic carcinoma cells leads to neuronal differentiation arrest. Depletion of Mest in primary hippocampal neurons via lentivirus expressing shMest or inducible KO system causes neurodegeneration. Notably, depletion of Mest in primary cortical neurons of rats leads to tau phosphorylation at the S199 and T231 sites. Overall, our data suggest that hypermethylation of the Mest promoter may cause or facilitate the progression of AD.

Details

Title
Hypermethylation of Mest promoter causes aberrant Wnt signaling in patients with Alzheimer’s disease
Author
Prasad Renuka 1 ; Jung Hwajin 1 ; Anderson, Tan 1 ; Song Yonghee 1 ; Moon Sungho 1 ; Shaker, Mohammed R 2 ; Sun, Woong 2 ; Lee, Junghee 3 ; Ryu Hoon 4 ; Lim, Hyun Kook 5 ; Eek-hoon, Jho 1 

 University of Seoul, Department of Life Science, Seoul, Republic of Korea (GRID:grid.267134.5) (ISNI:0000 0000 8597 6969) 
 Korea University College of Medicine, Department of Anatomy, Seoul, Republic of Korea (GRID:grid.222754.4) (ISNI:0000 0001 0840 2678) 
 Boston University School of Medicine, Boston University Alzheimer’s Disease Center and Department of Neurology, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558) 
 Boston University School of Medicine, Boston University Alzheimer’s Disease Center and Department of Neurology, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558); Korea Institute of Science and Technology, Center for Neuroscience, Brain Science Institute, Seoul, Republic of Korea (GRID:grid.35541.36) (ISNI:0000000121053345) 
 The Catholic University of Korea, Department of Psychiatry, Yeouido St. Mary’s Hospital, College of Medicine, Seoul, Republic of Korea (GRID:grid.411947.e) (ISNI:0000 0004 0470 4224) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2580183852
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.